Olanzapine

Oral olanzapine treats schizophrenia and manic/mixed episodes of bipolar I disorder in adults and adolescents 13–17. Adult bipolar I maintenance monotherapy is labeled; adolescent maintenance support is extrapolated from adult data. Adjunctive lithium/valproate acute bipolar treatment is an adult indication. Short-acting IM treats acute agitation with schizophrenia or bipolar I mania in adults; supporting trials were 24 hours, not a long-term depot regimen.

Relprevv is indicated for adult schizophrenia only after establishing oral olanzapine tolerability. Oral olanzapine plus fluoxetine treats bipolar I depressive episodes in adults and ages 10–17, and treatment-resistant depression in adults after 2 adequate antidepressant trials. Olanzapine monotherapy is not indicated for either depressive condition. Full fluoxetine/Symbyax contraindications, antidepressant warnings, titration and discontinuation require their own label review; no complete combination-dose algorithm is supplied here.

Recommended adult dose 10 mg; 5 or 7.5 mg may be appropriate. Consider 5 mg in older adults and 2.5 mg in debilitated or hypotension-prone patients. If needed, repeat up to 10 mg after assessment: safety of total doses above 30 mg/day, a second 10 mg injection sooner than 2 hours after the first, or a third sooner than 4 hours after the second is unstudied. Repeat-dose efficacy was not systematically evaluated. Assess orthostatic hypotension before each repeat and avoid further dosing with clinically significant postural BP fall. Deep IM only, never IV/subcutaneous. Reconstitute the 10 mg vial only with 2.1 mL sterile water; use within 1 hour. Parenteral benzodiazepine coadministration is not recommended; no universally safe spacing interval is inferred.

Only an enrolled health professional in a registered facility with emergency access administers deep gluteal IM, using supplied diluent and exact kit instructions. Establish oral tolerability first. Prescriber, pharmacy, facility and patient must enroll in the restricted program; do not dispense the kit directly to the patient. Observe continuously for at least 3 hours after every injection. Before release confirm alertness, orientation and no post-injection syndrome; symptoms can begin later. Arrange an escort to the destination and no driving/heavy machinery for the rest of that day. Suspected overdose-like delirium/sedation requires monitored medical care until resolved.

Selected olanzapine monotherapy and Relprevv labels list no formal contraindications. This does not establish safety in prior allergy or high-risk illness. When combined with fluoxetine, apply the separate full combination/fluoxetine contraindications; this ingredient profile does not substitute for that review.

Antipsychotic treatment increases death risk in older patients with dementia-related psychosis; olanzapine is not approved for that use. Relprevv also has a boxed warning for post-injection delirium/sedation syndrome, including coma, with restricted access and at least 3 hours of observation after each injection. Fluoxetine combination treatment adds its separate antidepressant suicidality warning and needs full combination review.

Common reactions include sleepiness, increased appetite/weight, constipation, dry mouth, dizziness and movement symptoms; IM treatment can cause hypotension. Postmarketing severe reactions include allergy, DRESS, diabetic crises, pancreatitis and muscle injury; spontaneous reports cannot establish incidence. Overdose can cause marked sedation/coma, delirium, agitation, speech/movement abnormalities, arrhythmia, hypotension, seizures and respiratory compromise. Obtain emergency/Poison Help assessment and professional airway/cardiovascular monitoring; no specific antidote exists. Relprevv-associated toxicity may require prolonged observation.

Use caution with CNS depressants and medicines lowering BP; avoid alcohol. Diazepam increases orthostatic effects. Parenteral benzodiazepines with short-acting IM are not recommended. Anticholinergic combinations increase hypomotility/urinary risks. Olanzapine can oppose levodopa/dopamine agonists. Review the independent lithium, valproate or fluoxetine labels when prescribed together.

Fluvoxamine inhibits CYP1A2 and can substantially increase olanzapine exposure; consider a lower olanzapine dose. Carbamazepine increases clearance; other enzyme inducers may do so. Smoking raises clearance, but labels do not mandate a fixed smoker dose increase. Reassess symptoms/tolerance when smoking or interacting medicines change; no universal percentage conversion is supplied. Activated charcoal decreases oral absorption and is a professional overdose consideration, not home management.

Olanzapine generally needs no renal adjustment and is not removed by dialysis. A small Child-Pugh A/B study showed little PK effect; it does not establish a severe-hepatic dosing rule. Individualize for hepatic reserve, interacting medicines, low BP and sensitivity. Older/debilitated patients may need lower starts and cautious titration; dementia-related psychosis is not an approved use. Relprevv’s specific sensitive-patient 150 mg every 4 weeks start differs from routine oral-target conversion.

Oral schizophrenia/manic-mixed treatment is labeled at 13–17, with greater weight/metabolic and sedation risks than adults. Bipolar depression at 10–17 requires fluoxetine combination treatment and separate review. Neither short-acting IM nor Relprevv has established pediatric safety/effectiveness; adult injection schedules are not pediatric regimens.

Available observational pregnancy data have not established a drug-associated major birth-defect risk, but do not guarantee safety. Balance untreated psychiatric illness and treatment risks; a pregnancy registry is available. Third-trimester exposure can cause neonatal movement/withdrawal symptoms, feeding or breathing problems requiring observation. Drug is present in milk; monitor the infant for excess sedation, irritability, poor feeding or abnormal movements. Raised prolactin may reversibly impair fertility.

The clinical mechanism is not fully established. Dopamine and serotonin receptor antagonism is proposed to contribute; histamine, muscarinic and adrenergic effects help explain sedation, anticholinergic effects and hypotension. Receptor binding does not establish an individual clinical response.

Oral

Peak about 6 hours; mean half-life about 30 hours (range 21–54). Steady state about 1 week; food does not alter absorption.

Short-acting IM

Peak about 15–45 minutes with higher early concentrations than oral treatment; elimination half-life is similar to oral, not depot.

Relprevv

Slow release controls kinetics; effective half-life about 30 days and concentrations may persist for months.

Metabolism / binding

Primarily glucuronidation and CYP1A2; CYP2D6 is a minor pathway. About 93% protein-bound.

Variation

Age, sex, smoking and interacting medicines affect clearance; individualized monitoring rather than a fixed combined-factor equation.

Assess psychiatric response, mood/suicide risk, adherence, sleepiness, falls and abnormal movements. Check fasting glucose and lipids at baseline and periodically, and weight regularly. Assess BP/orthostasis, bowel/urinary and swallowing problems, temperature/dehydration and prolactin symptoms. CBC is risk-directed, especially with prior low WBC or drug-related leukopenia; no universal ECG or fixed laboratory interval is inferred. Relprevv requires every-dose clinical observation and documented discharge criteria.

Avoid alcohol and assess driving effects; rise carefully and report fainting. Seek urgent help for high fever/rigidity/confusion, severe rash, severe thirst/urination, breathing/feeding problems or marked constipation. Do not stop/change doses or tobacco exposure without discussing the plan. For Zydis peel packaging with dry hands; it contains phenylalanine, with strength-specific amounts relevant to PKU. Relprevv visits require an escort and no driving for the rest of the day; report delayed confusion, unusual sleepiness or coordination problems immediately.

Ingredient / route

Olanzapine 5 mg · oral tablet.

Appearance / imprint

White round tablet; LILLY and 4115.

Example NDC / distributor

61269-631-30 · 30 tablets; H2-Pharma distribution under Cheplapharm license.

U.S. status

Prescription antipsychotic; no DEA schedule. Selected label record does not guarantee pharmacy stock.

Oral tablets

2.5, 5, 7.5, 10, 15 and 20 mg.

Zydis ODT

5, 10, 15 and 20 mg; yellow dissolving tablets, strength-specific imprints and phenylalanine content.

Short-acting IM

10 mg lyophilized single-dose vial; sterile-water reconstitution and acute supervised dosing.

Relprevv

210, 300 and 405 mg olanzapine-equivalent single-dose kits; 150 mg dose is prepared from the 210 mg kit. Pamoate salt mass is not the labeled olanzapine dose.

Scope

Products are not automatically interchangeable. Samidorphan or fluoxetine combination products and other brands require their complete labels.

Store selected oral and short-acting IM products at 20–25°C; protect oral tablets from light/moisture. Protect short-acting IM from light and freezing; use reconstituted solution within 1 hour and discard unused drug. Relprevv is stored at no more than 30°C; use only supplied diluent and exact reconstitution/aspiration instructions. Reconstituted depot suspension may remain in its vial for up to 24 hours at room temperature; resuspend, withdraw and inject immediately. Never confuse diluents, strengths, sites or observation requirements.